Evaluation of Hereditary Cancer Educational Videos

Active, not recruiting

• Conditions: Hereditary Cancer

• Registration Number: NCT06157801
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

To learn if educational videos can help participants be more informed about hereditary cancers (ones that run in the family).

Detailed Description

Primary Objective

Determine the impact of educational videos on:

* Participant's hereditary cancer knowledge.

* Participant's confidence to share hereditary cancer information with family members.

Secondary Objective

* Determine impact of educational videos on participant's confidence to undergo hereditary cancer screening.

* Identify opportunities to tailor and improve the educational video's content, style, and understandability per participant preferences and feedback.

Study Timeline

• Study First Submitted: 2023-11-27
• Study First Submitted QC: 2023-11-27
• Study First Posted: 2023-12-06
• Study Start: 2024-04-05
• Status Verified: 2025-09
• Last Update Submitted: 2025-09-04
• Last Update Posted: 2025-09-08
• Primary Completion: 2027-10-31
• Study Completion: 2027-10-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

1. Participants of The Harris Health System Lyndon B. Johnson (LBJ) Hospital outpatient oncology clinics (i.e., Gynecologic Oncology, Medical Oncology).
2. 18 years of age or older.
3. Speaks and/or reads English or Spanish.
4. Has a pathogenic or likely pathogenic variant (mutation) in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, and/or EPCAM on germline genetic testing.
5. Has a documented genetic testing results disclosure encounter (i.e. telephone call, follow-up appointment).

Exclusion Criteria

1. No longer receives outpatient care at LBJ Hospital at time of recruitment.
2. Has only a variant of uncertain significance in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, and/or EPCAM.
3. Has only a pathogenic or likely pathogenic variant in gene other than BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, or EPCAM.
4. Is unwilling, unable, or requires a legally authorized representative to provide informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hereditary Cancer Multidimensional Measure of Informed Choice Questionnaires	through study completion; an average of 1 year	Hereditary Cancer Multidimensional Measure of Informed Choice (MMIC); Knowledge Score scale: (1-8) true or false

Trial Locations

Locations (1)

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States